Dapagliflozin, a novel oral antidiabetic with an uncertain future
Objective: Diabetes mellitus type 2 (DM2) is one of the main sociosanitary problems; there are many treatments for it. Recently, it has been approved the first drug of a new family of oral hypoglycemic agents (OHA): dapagliflozin. We aimed to review the available scientific evidence on dapagliflozin...
Saved in:
| Main Authors: | Belén Escudero Vilaplana, María José Almodóvar Carretón, Silvia Herrero Hernández |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2014-11-01
|
| Series: | Farmacia Hospitalaria |
| Subjects: | |
| Online Access: | http://www.aulamedica.es/fh/pdf/7963.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Real-World Assessment of Efficacy and Safety Parameters for Dapagliflozin in Management of Type 2 Diabetes Mellitus: REWARD Study
by: Ahmed Hassoun, et al.
Published: (2022-01-01) -
Euglycemic diabetic ketoacidosis associated metabolic encephalopathy caused by dapagliflozin: a rare case report
by: Lulu Chu, et al.
Published: (2025-01-01) -
Deprescribing oral antidiabetics in elderly patients: Do electronic leaflets across the world address it?
by: Kitete Tunda Bunnel, et al.
Published: (2024-12-01) -
Combination of dapagliflozin and pioglitazone lacks superiority against monotherapy in streptozotocin-induced nephropathy
by: Aneta Cinakova, et al.
Published: (2025-01-01) -
Dapagliflozin for the treatment of heart failure with reduced ejection fraction in Brazil: a cost-effectiveness analysisResearch in context
by: Marcio Coutinho Xavier Naves, et al.
Published: (2025-02-01)